The mission of St. Jude Children's Research Hospital is to find cures for children with catastrophic illnesses through research and treatment. The resources of the hospital have been focused on pediatric cancer throughout its 44 year history and the Cancer Center has been supported by a CCSG for 29 years. Through the support of the American Lebanese Syrian Associated Charities (ALSAC), a separate corporation whose only purpose is to raise money in support of St. Jude Children's Research Hospital, patients are accepted without regard to ability to pay. Public support of the hospital through ALSAC provides a strong foundation for our Cancer Center upon which extramurally funded research and CCSG support can be leveraged to their fullest potential. In the current application, six multidisciplinary research programs are described. The Molecular Oncology (MO) and Signal Transduction (ST) Programs focus on basic, discovery-oriented research. The Developmental Therapeutics for Solid Malignancies (DTSM), Hematologic Malignancies (HM), Neurobiology and Brain Tumor (NBT), and Cancer Prevention and Control (CPC) Programs emphasize the translation of laboratory or population science to clinical application. The latter program is new to this application and represents the culmination of a long-standing commitment to long-term follow-up of our patient population, a recent commitment to population sciences, and successful recruitment of a world-class scientist to lead efforts in this area. Research by the 139 members of the Cancer Center is supported by 12 Shared Resources and an outstanding clinical research infrastructure. During the previous funding period, a new Cancer Center Director was appointed and the overall structure of our Cancer Center and its leadership were enhanced by several organizational changes, including bringing the infrastructure supporting the expansive clinical trials efforts administratively under the Cancer Center's authority. Several Program leader changes and the successful recruitment of three new outstanding Department Chairs (Immunology, Chemical Biology, and Epidemiology/Cancer Control) during the last funding period significantly enhance the multidisciplinary science done by our Cancer Center Programs. St. Jude Cancer Center investigators had over 2000 cancer-related publications during the funding period, 20% of which represented intraprogrammatic interactions and 15% of which were inter-programmatic. Extramural support for cancer research done at St. Jude is currently over $50 million per year, $31 million of which is from the NCI/HHMI. St. Jude Children's Research Hospital recently went through a vigorous Strategic Planning process and made a strong and long-term commitment to remain focused on cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-31
Application #
7637742
Study Section
Special Emphasis Panel (ZCA1-RTRB-Z (O1))
Program Officer
Marino, Michael A
Project Start
1997-04-01
Project End
2013-02-28
Budget Start
2009-03-01
Budget End
2010-02-28
Support Year
31
Fiscal Year
2009
Total Cost
$5,973,490
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Sadighi, Zsila S; Curtis, Elizabeth; Zabrowksi, Jennifer et al. (2018) Neurologic impairments from pediatric low-grade glioma by tumor location and timing of diagnosis. Pediatr Blood Cancer 65:e27063
Wierdl, Monika; Tsurkan, Lyudmila; Chi, Liying et al. (2018) Targeting ALK in pediatric RMS does not induce antitumor activity in vivo. Cancer Chemother Pharmacol 82:251-263
Penkert, Rhiannon R; Hurwitz, Julia L; Thomas, Paul et al. (2018) Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia. Haematologica 103:e50-e54
Turner, Benjamin L; Brenes-Arguedas, Tania; Condit, Richard (2018) Pervasive phosphorus limitation of tree species but not communities in tropical forests. Nature 555:367-370
Buchman, Cameron D; Chai, Sergio C; Chen, Taosheng (2018) A current structural perspective on PXR and CAR in drug metabolism. Expert Opin Drug Metab Toxicol 14:635-647
Gibbs, E B; Kriwacki, R W (2018) Direct detection of carbon and nitrogen nuclei for high-resolution analysis of intrinsically disordered proteins using NMR spectroscopy. Methods 138-139:39-46
Pui, Ching-Hon; Liu, Yiwei; Relling, Mary V (2018) How to solve the problem of hypersensitivity to asparaginase? Pediatr Blood Cancer 65:
Mukkada, Sheena; Smith, Cristel Kate; Aguilar, Delta et al. (2018) Evaluation of a fever-management algorithm in a pediatric cancer center in a low-resource setting. Pediatr Blood Cancer 65:
Zhong, Bo; Maharaj, Anil; Davis, Abigail et al. (2018) Development and validation of a sensitive LC MS/MS method for the measurement of the checkpoint kinase 1 inhibitor prexasertib and its application in a cerebral microdialysis study. J Pharm Biomed Anal 156:97-103
van Oosterwijk, Jolieke G; Buelow, Daelynn R; Drenberg, Christina D et al. (2018) Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. J Clin Invest 128:369-380

Showing the most recent 10 out of 6764 publications